# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
EF Hutton analyst Tim Moore maintains VolitionRX (AMEX:VNRX) with a Buy and maintains $4 price target.
Cantor Fitzgerald analyst Ross Osborn reiterates VolitionRX (AMEX:VNRX) with a Overweight and maintains $2.5 price target.
EF Hutton analyst Tim Moore maintains VolitionRX (AMEX:VNRX) with a Buy and maintains $4.5 price target.
VolitionRX (AMEX:VNRX) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.11) by 9...
Cantor Fitzgerald analyst Ross Osborn reiterates VolitionRX (AMEX:VNRX) with a Overweight and maintains $2.5 price target.
EF Hutton analyst Tim Moore maintains VolitionRX (AMEX:VNRX) with a Buy and maintains $4.5 price target.